BMO Capital analyst Andrew Strelzik maintains Constellation Brands (NYSE:STZ) with a Outperform and lowers the price target from $290 to $265.
7 Analysts Have This to Say About CymaBay Therapeutics
Over the past 3 months, 7 analysts have published their opinion on CymaBay Therapeutics (NASDAQ:CBAY) stock. These analysts…